ArticleInternational journal of critical illness and injury science
Prognostic accuracy of mid-regional proadrenomedullin in patients with sepsis - A longitudinal observational study.
Article in International journal of critical illness and injury science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognostication in sepsis remains challenging as conventional scores and biomarkers, including procalcitonin (PCT) and lactate, show limited predictive strength when used alone. This study evaluated the ability of mid-regional proadrenomedullin (MR-proADM) to predict 14-day mortality in patients with sepsis, intending to improve early risk stratification. Methods: A prospective observational study was conducted at a tertiary hospital in North India over 18 months. One hundred and twenty patients admitted to the intensive care unit (ICU) and ward with sepsis were enrolled. On admission, serum MR-proADM, PCT, and lactate were measured, and Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were calculated. Prognostic accuracy was determined using the receiver operating characteristic (ROC) analysis. Results: The mean age of the participants was 45.9 ± 16.1 years, with 54.2% male. Nonsurvivors ( Conclusion: MR-proADM is a reliable adjunctive prognostic biomarker for sepsis and may enhance early risk stratification when used alongside established scores and biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.